Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid, When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease

Authors not listed

Wyeth is now a wholly owned subsidiary of Pfizer · 2007

Abstract

To assess the pharmacodynamics (PD) of biomarkers amyloid beta peptide 40 and 42 (Ab40 and Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy young subjects and patients with Alzheimer Disease (AD).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2007). A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid, When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease. <em>Wyeth is now a wholly owned subsidiary of Pfizer</em>. https://clinicaltrials.gov/study/NCT00479219
Vancouver
Anonymous. A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid, When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease. Wyeth is now a wholly owned subsidiary of Pfizer. 2007.
BibTeX
@misc{anon2007ASingl, title = {A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid, When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease}, author = {Anonymous}, journal = {Wyeth is now a wholly owned subsidiary of Pfizer}, year = {2007}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings